Selective inhibitor of SIRT2 (IC50 = 3.5 μM). Displays no activity at SIRT1 and SIRT3 at concentrations up to 40 μM. Reduces α-synuclein-mediated toxicity in in vitro and in vivo models of Parkinson's disease.